Oncologists explain why ALK+ NSCLC patients switch therapies

Click here to subscribe to Fiercebiotech.com

3 years ago

Html
Text

Download the Report

This week's Fierce Pharma is brought to you by OptimizeRx.
Trouble viewing? Click here.

optimizerx.com

Download the Report: Discover the Drivers of Treatment Discontinuation and Switching in ALK+ NSCLC Patients

Competition will only grow in the ALK+ NSCLC treatment landscape as emerging therapies join current drug options. Standing out in this limited patient population will be more important than ever before.

OptimizeRx surveyed oncologists across the U.S. to find out:

Which ALK+ NSCLC treatments are most highly ranked on a variety of key attributes

How oncologists educate patients about their prescribed treatment,
financial assistance options and
patient support programs

Why at least 25% of patients with ALK+ NSCLC discontinue or switch treatment

Download the report today and discover new opportunities in the crowded ALK+ NSCLC market.

OptimizeRx Corporation | 400 Water Street, Suite 200 | Rochester, MI

Want to reach 160,000+ Fierce Pharma subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.

You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Pharma's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Oncologists explain why ALK+ NSCLC patients switch therapies

Download the Report:Discover the Drivers of TreatmentDiscontinuation and Switching in ALK+ NSCLC Patients

Share on

Other newsletters from Fiercebiotech.com

Related newsletters

Download the Report:
Discover the Drivers of Treatment
Discontinuation and Switching in ALK+ NSCLC Patients